יחס שווי פעילות לרווח לפני ריבית, מסים ופחת Vivani (VANI)

Vivani Medical, Inc. (VANI) relies on patent protection and the complexities of FDA certification, which effectively bars smaller players from the market. The company's US laboratories are developing extended-release drug delivery systems to combat obesity and diabetes. The confirmed price history on the chart shows that the EV/EBITDA dynamic is currently at 0.00. A stable research regime and the humanitarian status of its developments minimize external risks, ensuring sustainable business growth.

The implementation of ESG standards and energy-efficient factories at Vivani Medical (VANI) requires significant capital expenditures, making the tracking of debt load critically important. This indicator compares the total enterprise value (EV) with earnings before interest, taxes, depreciation, and amortization (EBITDA), allowing investors to assess the real value of assets inclusive of debt, which the historical EV/EBITDA dynamics of the company clearly reflect.